Children's Oncology Group's 2013 blueprint for research: renal tumors
Authors
Dome, Jeffrey S.Fernandez, Conrad V.
Mullen, Elizabeth A.
Kalapurakal, John A.
Geller, James I.
Huff, Vicki
Gratias, Eric J.
Dix, David B.
Ehrlich, Peter F.
Khanna, Geetika
Malogolowkin, Marcio H.
Anderson, James R.
Naranjo, Arlene
Perlman, Elizabeth J.
UMass Chan Affiliations
Quality Assurance Review CenterDocument Type
Journal ArticlePublication Date
2013-06-01
Metadata
Show full item recordAbstract
Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented.Source
Pediatr Blood Cancer. 2013 Jun;60(6):994-1000. doi: 10.1002/pbc.24419. Epub 2012 Dec 19. Link to article on publisher's siteDOI
10.1002/pbc.24419Permanent Link to this Item
http://hdl.handle.net/20.500.14038/46472PubMed ID
23255438Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1002/pbc.24419